Nothing Special   »   [go: up one dir, main page]

EA200200321A1 - Апоптин-ассоциированный белок - Google Patents

Апоптин-ассоциированный белок

Info

Publication number
EA200200321A1
EA200200321A1 EA200200321A EA200200321A EA200200321A1 EA 200200321 A1 EA200200321 A1 EA 200200321A1 EA 200200321 A EA200200321 A EA 200200321A EA 200200321 A EA200200321 A EA 200200321A EA 200200321 A1 EA200200321 A1 EA 200200321A1
Authority
EA
Eurasian Patent Office
Prior art keywords
apoptin
associated protein
new
relates
present
Prior art date
Application number
EA200200321A
Other languages
English (en)
Other versions
EA005933B1 (ru
Inventor
Матиу Хубертус Мария Нотеборн
Астрид Адриана Анна Мария Данен-Ван Орсот
Original Assignee
Леадд Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99202858A external-priority patent/EP1081226A1/en
Priority claimed from EP99203465A external-priority patent/EP1108785A1/en
Application filed by Леадд Б.В. filed Critical Леадд Б.В.
Publication of EA200200321A1 publication Critical patent/EA200200321A1/ru
Publication of EA005933B1 publication Critical patent/EA005933B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к области апоптоза. Настоящее изобретение относится к новым возможностям для терапии, например к новым способам сочетанной терапии или новым терапевтическим соединениям, которые могут работать сами по себе, последовательно или совместно с апоптином, особенно в таких случаях, когда р53 является (частично) нефункциональным.Отчет о международном поиске был опубликован 2001.09.20.
EA200200321A 1999-09-02 2000-09-01 Апоптин-ассоциированный белок EA005933B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99202858A EP1081226A1 (en) 1999-09-02 1999-09-02 Apoptin-associating protein
EP99203465A EP1108785A1 (en) 1999-10-21 1999-10-21 Apoptin-associating protein
PCT/NL2000/000612 WO2001016165A2 (en) 1999-09-02 2000-09-01 Apoptin-associating protein

Publications (2)

Publication Number Publication Date
EA200200321A1 true EA200200321A1 (ru) 2002-08-29
EA005933B1 EA005933B1 (ru) 2005-08-25

Family

ID=26153361

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200321A EA005933B1 (ru) 1999-09-02 2000-09-01 Апоптин-ассоциированный белок

Country Status (20)

Country Link
US (2) US7317096B1 (ru)
EP (1) EP1083224B1 (ru)
JP (1) JP2003510030A (ru)
CN (1) CN100513565C (ru)
AT (1) ATE347597T1 (ru)
AU (1) AU781127B2 (ru)
BR (1) BR0013743A (ru)
CA (1) CA2383784A1 (ru)
CY (1) CY1106355T1 (ru)
DE (1) DE60032201T2 (ru)
DK (1) DK1083224T3 (ru)
EA (1) EA005933B1 (ru)
ES (1) ES2277815T3 (ru)
HU (1) HUP0202688A2 (ru)
IL (2) IL148469A0 (ru)
NO (1) NO20021067L (ru)
NZ (1) NZ517740A (ru)
PL (1) PL204275B1 (ru)
PT (1) PT1083224E (ru)
WO (1) WO2001016165A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042461A2 (en) * 1999-12-10 2001-06-14 Leadd B.V. Apoptin-associating protein
EP2288715B1 (en) 2008-04-11 2014-09-24 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2011100428A2 (en) * 2010-02-10 2011-08-18 The Uab Research Foundation Compositions for improving bone mass

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
EP0878546A1 (en) * 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
AU4388296A (en) 1994-12-22 1996-07-10 Novartis Ag Nuclear protein serine/threonine kinases
JPH11506340A (ja) * 1995-06-07 1999-06-08 アエスキュラープ ビー．ヴィ． アポプチンの利用と方法
WO1998039448A2 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
SK286235B6 (sk) * 1997-08-12 2008-06-06 Leadd B. V. Spôsob zisťovania transformačnej schopnosti látky, spôsob zisťovania predispozície buniek stať sa nádorovými bunkami, použitie nukleovej kyseliny a diagnostická súprava
EP0921192A1 (en) 1997-12-03 1999-06-09 Leadd B.V. Molecules interacting with apoptin
EP0924296A3 (en) * 1997-12-03 2001-08-01 Leadd B.V. Methods and means for inducing apoptosis by interference in RNA processing
EP0927757A1 (en) * 1997-12-03 1999-07-07 Leadd B.V. Methods and means for inducing apoptosis by interfering with Bip-like proteins
US20030105315A1 (en) 1998-04-09 2003-06-05 Metagen Pharmaceuticals Gmbh Human nucleic acid sequences from ovarian tumor tissue
EP1075518A2 (en) * 1998-05-05 2001-02-14 Incyte Pharmaceuticals, Inc. Human transcriptional regulator molecules
EP1106691A1 (en) 1999-12-10 2001-06-13 Leadd B.V. Apoptin-associating protein
WO2001042461A2 (en) 1999-12-10 2001-06-14 Leadd B.V. Apoptin-associating protein
EP1111045A3 (en) 1999-12-10 2001-09-19 Leadd B.V. Apoptin-associating protein
WO2001053351A2 (en) 2000-01-17 2001-07-26 Leadd B.V. Apoptin bindendes protein
EP1138765A1 (en) 2000-03-27 2001-10-04 Leadd B.V. Apoptin-associating proteins AAP-5 and AAP-6

Also Published As

Publication number Publication date
WO2001016165A3 (en) 2001-09-20
NO20021067D0 (no) 2002-03-04
AU781127B2 (en) 2005-05-05
EP1083224A2 (en) 2001-03-14
US7317096B1 (en) 2008-01-08
CN1387569A (zh) 2002-12-25
NO20021067L (no) 2002-05-02
IL148469A (en) 2009-02-11
DE60032201T2 (de) 2007-09-20
JP2003510030A (ja) 2003-03-18
EA005933B1 (ru) 2005-08-25
CA2383784A1 (en) 2001-03-08
CY1106355T1 (el) 2011-10-12
ATE347597T1 (de) 2006-12-15
NZ517740A (en) 2003-09-26
DE60032201D1 (de) 2007-01-18
BR0013743A (pt) 2005-01-11
WO2001016165A2 (en) 2001-03-08
CN100513565C (zh) 2009-07-15
PL354285A1 (en) 2003-12-29
ES2277815T3 (es) 2007-08-01
DK1083224T3 (da) 2007-04-10
HUP0202688A2 (en) 2002-12-28
IL148469A0 (en) 2002-09-12
EP1083224B1 (en) 2006-12-06
PT1083224E (pt) 2007-03-30
AU7324200A (en) 2001-03-26
US20080176231A1 (en) 2008-07-24
PL204275B1 (pl) 2009-12-31
US7767790B2 (en) 2010-08-03
EP1083224A3 (en) 2001-04-25

Similar Documents

Publication Publication Date Title
EA199800667A1 (ru) Новые фенантридины
EA199900620A1 (ru) Фталазиноны
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
EA199900758A1 (ru) Малые молекулы, полезные при лечении воспалительных заболеваний
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA199900421A1 (ru) Бензонафтиридины в качестве бронхиальных терапевтических средств
EA200200530A1 (ru) Гетероциклические замещенные пиразолоны
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
EA200500856A1 (ru) Новые химические соединения
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
EA200201214A1 (ru) Замещенные тиоацетамиды
GB9406857D0 (en) Improvements in or relating to organic compounds
DE60011100D1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
EA199900643A1 (ru) Сульфамидные ингибиторы металлопротеаз
DE69919700D1 (de) Überbrückte indenopyrrolocarbazole
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
EA200000519A1 (ru) 2-АРИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
SE9801494D0 (sv) Novel use
EA200100517A1 (ru) Антагонисты 5ht1 для антидепрессантной терапии
EA200100854A1 (ru) Кальций-литические соединения
EA199900534A1 (ru) Имидазопиридазины
EA200000520A1 (ru) 2-АРИЛ-3-АРОИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
EA200200798A1 (ru) Кальцилитические соединения
EA200200321A1 (ru) Апоптин-ассоциированный белок

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU